Nektar Therapeutics Ratios and Metrics

Market cap in millions MXN. Fiscal year is January - December.

Millions MXN. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jan '26 Jan 9, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	19,636	3,575	1,822	8,286	51,115	60,686
Market Cap Growth	494.99%	96.17%	-78.01%	-83.79%	-15.77%	-15.27%
Enterprise Value	17,858	2,680	-338	3,485	38,260	42,121
Last Close Price	693.50	270.00	766.65	4653.90	4653.90	6186.60
PS Ratio	17.10	1.74	1.20	4.61	24.47	19.94
PB Ratio	12.58	2.82	0.82	1.16	3.67	2.83
P/TBV Ratio	12.58	2.82	0.82	1.46	4.14	3.05
EV/Sales Ratio	16.55	1.31	-	1.94	18.31	13.84
EV/FCF Ratio	-5.11	-	-	-	-	-
Debt / Equity Ratio	1.96	3.20	1.76	0.78	0.50	0.33
Asset Turnover	0.21	0.28	0.16	0.10	0.08	0.09
Inventory Turnover	-	-	1.91	1.24	1.60	1.39
Quick Ratio	4.09	4.18	5.97	7.53	8.90	9.55
Current Ratio	4.24	4.26	6.45	8.01	9.34	9.83
Return on Equity (ROE)	-180.24%	-124.10%	-110.95%	-70.39%	-59.64%	-35.80%
Return on Assets (ROA)	-27.98%	-23.14%	-15.25%	-16.43%	-21.00%	-13.51%
Return on Invested Capital (ROIC)	-	-450.92%	-131.09%	-111.04%	-137.22%	-81.99%
Return on Capital Employed (ROCE)	-58.00%	-53.60%	-39.00%	-37.40%	-43.20%	-26.70%
Earnings Yield	-11.28%	-69.35%	-256.12%	-86.68%	-21.01%	-14.57%
FCF Yield	-17.78%	-103.28%	-179.50%	-72.91%	-17.15%	-10.51%
Buyback Yield / Dilution	-14.07%	-8.24%	-1.53%	-2.10%	-2.64%	-2.05%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.